177Lu-trastuzumab proved effective in targeting HER2-positive breast cancer lesions with great specificity and was a potential palliative agent for radioimmunotherapy in HER2-positive metastatic breast disease [98,99]. This evidence concerns the gene ERBB2 and breast carcinoma.